Graves’ orbitopathie (TED, Thyroid Eye Disease) | AmgenPro

Wilt u deze externe website bezoeken en amgenpro.nl verlaten?

U verlaat nu deze Amgen Nederland website. Amgen Nederland draagt geen verantwoordelijkheid voor, en oefent geen controle uit, over de organisaties, meningen or juistheid van de informatie van de server of website waar u naar toegaat.

Nee, ga terug naar amgenpro.nl Ja, verlaat amgenpro.nl

Over Graves' orbitopathie (TED, Thyroid Eye Disease)

logincta logincta

AmgenPro is uitsluitend bedoeld voor professionele zorgverleners in Nederland

Log in met een AmgenPro account voor toegang tot content. Of maak een account* aan met BIG-nummer en ontdek alle voordelen.
*Een AmgenPro account is uitsluitend aan te maken door een beroepsbeoefenaar (een zorgprofessional met voorschrijf- of terhandstellingsbevoegdheid).
Support

Hoewel Graves’ orbitopathie vaak geassocieerd is met de ziekte van Graves, volstaat de behandeling van de schildklieraandoening niet om ook de oogklachten te behandelen. Ook patiënten met een normale schildklierfunctie kunnen Graves’ orbitopathie krijgen. De reden hiervoor is dat de pathofysiologie van Graves’ orbitopathie anders is dan die van schildklieraandoeningen en hierbij naast de thyrotropin (TSH) receptor, ook de insuline-achtige groeifactor-1 (IGF-1) receptor betrokken is.1,2
Graves’ orbitopathie kan zich uiten in een breed spectrum van zichtbare en niet-zichtbare manifestaties3 Graves’ orbitopathie is meer dan alleen proptose.
Wanneer uw patiënten een van de volgende tekenen of symptomen vertonen, kan er sprake zijn van Graves’ orbitopathie.3
zichtbare tekenen
Bekijk de video voor meer uitleg over Graves’ orbitopathie (TED)
  • Overview
  • Transcriptie
Thyroid eye disease, or TED, is a disease affecting the eyes.1
TED is also referred to as Graves' eye disease.2
TED can develop in patients with Graves' disease.
Although they are both autoimmune conditions, TED and Graves' disease are different conditions, as they affect different parts of the body.
In Graves' disease, the body mistakenly attacks the thyroid gland.
resulting in an overactive thyroid, or hyperthyroidism.
In TED, the immune system attacks the muscles and fat tissues behind the eyes, causing redness and swelling known as inflammation.
This process results in both the muscles and fat tissues behind the eyes expanding, as well as build up the fluid.
Treatments for Graves' disease are targeted to help the thyroid, but won't help TED.
Different medications and specialists are required to manage each condition.3
Some of the early symptoms of TED are eye pain, redness, dry or gritty eyes, or overly watery eyes, and blurry vision.1,2
These symptoms can be mistaken for other conditions, such as allergies. TED is a progressive disease, which means it can get worse over time.
Bulging eyes and eyelid swelling may occur as TED progresses.
Eye swelling can make it hard to move the eyes.
All these effects can lead to vision impairment, including double vision.
In some cases, it is possible for the swelling of fat and muscle tissue to push against the optic nerve, which puts vision at risk.4
While it is not entirely known why some people develop TED and others do not,
Doctors have found certain factors that put people at greater risk.
This includes having a thyroid condition, such as Graves' disease or hyperthyroidism, and Hashimoto's disease or hypothyroidism.
The risk of developing TED may also be increased if patients have received radioactive iodine as treatment for Graves' disease.
In general, women are more likely to suffer from TED.
Smoking and middle age further increase the risk of developing the condition.
TED treatment requires a specialist who's familiar with treating it.5
Remember, TED can get worse over time.
Getting treatment as early as possible can help prevent further eye damage.
References:
  1. Perros, P. Et al. (2009) Thyroid Eye Disease. BMJ; 338:b650, 645-650.
  2. Weiler, D. (2017). Thyroid eye disease: a review. Clinical and Experimental Optometry; 100:20-25.
  3. Davies, F. Et al (202) Graves’ disease. Nature Reviews; 6:52, 1-23.
  4. Jain, A., et al. (2021) Theyroid eye Disease: Redefining its manamangement- A review. Clinical and Experimental Opthalmology; 49;2023-211.
  5. McAlinden, C. (2014). An overview of thyroid eye disease. Eye and Vision; 1:9, 1-4.
  6. Barrio-Barrio, et al. (2015). Graves’ Opthalmology: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Opthalmology; 1-16.
matige-tot-ernstige GO

  • Referenties:

    1. Bahn RS. New Eng J Med. 2010;362:726-738
    2. Bartalena L, et al. Front Endocrinol. 2020;11:615993
    3. Weiler DL. Clin Exp Optom. 2017;100:20-25
    4. Bartalena L, et al. Eur J Endocrinol. 2021;185:G43-G67
    5. Barrio-Barrio J, et al. J Opthslmol. 2015; 2015:249125
    NLD-632-25-80018/nov2025
TepezzaTepezza

Tepezza® (teprotumumab)

Tepezza is een behandeling voor volwassen patiënten met matige tot ernstige Graves’ orbitopathie (TED, Thyroid Eye Disease). Bekijk de Tepezza® pagina voor meer informatie en voorlichtingsmaterialen.
Back to Top